|Past two years||Past Year||Past 30 Days|
|Full Text Views||2||0||0|
The repository preparation of cycloguanil pamoate (Camolar®, CI-501) was tested therapeutically against malaria in West Pakistan. Three of the 40 villagers who were treated had recrudescences of their falciparum infections.
The parasite from one of these individuals was established in prisoner volunteers and tested for its susceptibility to various antimalarials. The results of these studies indicated that this strain of falciparum malaria was resistant to chlorguanide and pyrimethamine but susceptible to mepacrine, chloroquine, and quinine.
Laboratory of Parasite Chemotherapy, NIAID, NIH, Malaria Project, U. S. Penitentiary, Atlanta, Georgia.
Chief, Laboratory of Parasite Chemotherapy, NIAID, NIH, Bethesda, Maryland.
Present address: Department of Medicine, University Hospital, Syracuse, New York.